Clinical trials: Cancer, suspended
Leukemia, Lymphoma
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
- Trial name
- NCT00077493
- Testing
- BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- MedImmune LLC
Breast Cancer
Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)
This intraoperative study is a prospective study analyzing specimens from fifty subjects. Patients scheduled to undergo breast-conserving surgery will be recruited in accordance with the inclusion and exclusion criteria.
- Trial name
- NCT02313116
- Testing
- Interferometric Synthetic Aperture Microscopy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Diagnostic Photonics, Inc.
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS).
- Trial name
- NCT04278768
- Testing
- Emavusertib, Venetoclax
- Where
- 32 sites in United States, Czechia and 6 more
- Volunteers
- 366 people
- Sponsor
- Curis, Inc.
Relapsed or Refractory Lymphoma Including ENKL
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose…
- Trial name
- NCT06761677
- Testing
- Brincidofovir
- Where
- 8 sites in China, Japan and 1 more
- Volunteers
- 43 people
- Sponsor
- SymBio Pharmaceuticals
Metastatic Castrate Resistant Prostate Cancer
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Demonstrate detection of ARv7 splice variant transcripts from exosomes in the circulation of MCRPC patients pre and post treatment with selective Androgen pathway inhibitors (i.e. abiraterone and enzalutamide)
- Trial name
- NCT03236688
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Metastatic Solid Tumors
A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors
The aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose).
- Trial name
- NCT00827203
- Testing
- Elesclomol Sodium
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Synta Pharmaceuticals Corp.
Bladder Cancer
Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay
The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer.
- Trial name
- NCT05643690
- Testing
- UriFind Bladder Cancer Assay
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- AnchorDx Medical Co. Ltd. US
Multiple Myleoma, Refractory and Relapsed Multiple Myeloma
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
This study is a single-arm, investigator-initiated clinical trial. The primary objective is to evaluate the safety and preliminary efficacy of administering universal BCMA CAR-T cells to subjects with refractory and relapsed…
- Trial name
- NCT06663046
- Testing
- Single dose injection of certain dose of UWD-00B, MMF Immunosuppression
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Wondercel Biotech (ShenZhen)
Glioblastoma Multiforme, Glioblastoma
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor
- Trial name
- NCT06329570
- Testing
- NaviFUS System, Lumason, Bevacizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NaviFUS Corporation
Osteosarcoma, Soft Tissue Sarcoma
Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
This is a open-Label, dose-escalation study to evaluate the safety, tolerability and antitumor activity of DIT309 in subjects with advanced bone and soft tissue sarcomas.The study also plan to explore the Maximum Tolerated Dose…
- Trial name
- NCT07052383
- Testing
- DIT309 cell injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tcelltech Inc.
CRC (Colorectal Cancer), Metastatic Colorectal Cancer
Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer
This is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (REVO-UWD-01) in the metastatic colorectal cancer.
- Trial name
- Wondercel-UWD1 (NCT06653010)
- Testing
- Universal CAR-T cells injection for treating mCRC
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Wondercel Biotech (ShenZhen)
Glioma
ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma
This study is designed to assess the safety and feasibility of using the ExAblate, Type 2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma.
- Trial name
- NCT03322813
- Testing
- ExAblate 4000 - Type 2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- InSightec
Chronic Lymphocytic Leukemia (CLL)
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
This study will evaluate effectiveness and safety in routine clinical practice in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).
- Trial name
- REVEAL (NCT03659669)
- Where
- 13 sites in Israel
- Volunteers
- 272 people
- Sponsor
- AbbVie
Fallopian Tube Cancer, Ovarian Cancer
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This is a Phase I, multicenter, open-label, dose-escalation study of single-agent D4064A administered by IV infusion to patients with recurrent or persistent epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), and…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT00753480
- Testing
- D4064A
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Genentech, Inc.
B-cell Chronic Lymphocytic Leukemia
Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
This is a phase II, prospective, multicenter, open-label study to evaluate the efficacy and safety of Alemtuzumab in patients with relapse and refractory B-cell chronic lymphocytic leukemia.
- Trial name
- CLL004 (NCT01982175)
- Testing
- Alemtuzumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Zhangjiang Biotechnology Limited Company
Non-small Cell Lung Cancer, Colorectal Cancer
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 5,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the…
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
- Trial name
- NCT04638751
- Testing
- Immunotherapy, Chemotherapy, CRC surgical resection
- Where
- 10 sites in United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Persephone Biosciences
Renal Cell Carcinoma (RCC), Lung Cancer
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas, Ovarian Cancer
- Trial name
- NCT07181720
- Testing
- CD70-targeted CAR-T cells
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
NSCLC
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
The primary purpose of this study is to compare the progression-free survival (PFS) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2)…
- Trial name
- PINNACLE (NCT05378763)
- Testing
- Poziotinib, Docetaxel
- Where
- United States
- Volunteers
- 268 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Solid Tumors
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy.
- Trial name
- NCT05155332
- Testing
- BI 1831169, anti-PD-1 antibody
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 190 people
- Sponsor
- Boehringer Ingelheim